One Ms really?

Discussion in 'Novartis' started by anonymous, Jan 12, 2021 at 12:34 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Unsure what the point Des was trying to make on stage. Went on for long time
     

  2. anonymous

    anonymous Guest

    it was all about him. that’s why he wanted everyone in Chicago. He wanted to feed his ego. Uninspired and flat, he isn’t a leader. the meeting was a waste except for the little time we got in our own franchise breakouts. and note to Dez: the ms team has always been account selling. thanks for the most basic 101 training i’ve ever had to sit through.
     
  3. anonymous

    anonymous Guest

    Ditto in respiratory. We sell a biologic that is buy and bill and specialty pharmacy and requires a prior authorization. Going on 20 years of account selling since Xolair is going on its 20th year
     
  4. anonymous

    anonymous Guest

    Except dupixent is knocking on our door and taking market share for asthma.
     
  5. anonymous

    anonymous Guest

    3 new biologic entrants to the asthma market in 5 years. Yeah, they’re going to take a little share dumb A, what’s your point. Xolair revenue still solid, pays for your lazy ass to work here.
     
  6. anonymous

    anonymous Guest

    Anyone who knows Xolair knows that we lose a ton of patients for - their IgE level being out of range, mo presence on allergen, malignancy warning and black box, and cost to Medicare patients. Other biologics sadly have better resources for Medicare patients when it comes to their free drug program if they need it. Just lost a patient today because they have no Medicare secondary insurance, our asthma foundations are closed and they don’t qualify for the genentech free drug program. Their out of pocket would be 350 a month if they get Xolair so guess what, they are getting another biologic that has a better free drug program. Just one example why we are losing
     
  7. anonymous

    anonymous Guest

    That’s the reason i’m not working here anymore smarty and attitudes like yours. Xolair has run its course and I couldn’t be happier to be leaving this culture.
     
  8. anonymous

    anonymous Guest

    Hahaha, now I’m the bad person for setting you straight. Project much?....goodbye Felicia, don’t let the door hit you in the A. I’m sure you’ll find a safe space...............eventually.
     
  9. anonymous

    anonymous Guest

    Not the OP…but he/she went out with some class and just making a point that’s valid. Sounds like someone is bitter. Another reminder, spread some kindness to all of us still working here instead of hate. NVS isn’t the same company I joined years ago and the last few years is evident of that with the downsizing in almost every division.
     
  10. anonymous

    anonymous Guest

    When your nemesis Genentech's BTKi is approved you are all going to be toast anyway.
     
  11. anonymous

    anonymous Guest

    Haha yes, a moderate to low efficacy oral is going to take Kesimpta market share. Idiot. You are just as stupid as the morons that green lit a twice a day moderate to low efficacy oral lol.
     
  12. anonymous

    anonymous Guest

    Well ocrevus did hurt when launched so if the data is good I would say so. Heck, most of the good abl’s and reps were either let go last year or left on their own accord. Hopefully, I’m on my way out of here pending official offer letter :)
     
  13. anonymous

    anonymous Guest

    How much time can we waste with this account based selling. You know in 3 months this will never be discussed ever again. Another waste of money by Novartis.
     
  14. anonymous

    anonymous Guest

    Yet how much time are they taking away from the field for us to review the modules, so in person coaching and then discuss with another coaching session and yet another coaching session for live role plays. Whose friends with the owner of the rain group I wonder. Someone’s buddies are getting paid a shit ton to waste our time
     
  15. anonymous

    anonymous Guest


    Dez must be getting a kickback for this. This may be the worst crap Novartis bought. This is so basic most of us have 10-20 years of experience. Like the other poster said in 3 months this will be gone. Yet we wasted all this time.
     
  16. anonymous

    anonymous Guest


    Or is it our new VP of training? Maybe this is his brainchild
     
  17. anonymous

    anonymous Guest

    Account Based selling, incorporating AI, HCP surveys and "Next Best Action". I think there are consulting agencies talking to all the big pharmas, feeding us all the same crap trying to be the future and relevant and edgy. With access at an all time low pharmas are desperate to differentiate themselves and progress forward so they are buying into these concepts from the consultants and running with it (millions invested!).
     
  18. anonymous

    anonymous Guest

    Great moron rep take!
     
  19. anonymous

    anonymous Guest

    You are the moron. Douche Bag.
     
  20. anonymous

    anonymous Guest

    Kesimpta market share still on the upswing!